What if it's possible to revolutionize drug design?

We think it is

What if it's possible to be part of changing the world?

We think it is

What if it's possible to send patients home, disease-free?

We think it is

Shaping new possibilities for patients everywhere

Zymeworks is a clinical-stage biotechnology company united in creating disruptive therapeutic platforms and impactful biotherapeutics that return patients to their loved ones, disease-free.

For Patients

Pipeline of Potential

Lead Product Candidates

Preclinical
Phase 1
Phase 2
Pivotal
Commercial Rights

ZW25

HER2 x HER2 Bispecific Antibody

  • Azymetric™
Phase 2
BeiGene rights in Asia Pacific countries including China, South Korea, Australia, and New Zealand but excluding Japan.
  • Biliary Tract Cancer
  • Breast Cancer
  • Gastroesophageal Adenocarcinomas
  • Other HER2-Expressing Cancers
Full Details
  • Biliary Tract Cancer
  • Gastroesophageal Adenocarcinomas
  • Breast Cancer
  • Other HER2-Expressing Cancers
  • Phase 1

    Single Agent & Chemotherapy Combination

    Now Enrolling Patients
  • 1st Line Gastroesophageal Adenocarcinomas
  • Phase 2

    Chemotherapy Combination

    Now Enrolling Patients
  • Breast Cancer
  • Phase 2

    Combination with Palbociclib & Fulvestrant

    Now Enrolling Patients

    ZW49

    HER2 x HER2 Bispecific Antibody Drug Conjugate (ADC)

    • Azymetric™
    • ZymeLink™
    Phase 1
    • HER2-Expressing Cancers
    Full Details
  • HER2-Expressing Cancers
  • Phase 1

    Single Agent

    Now Enrolling Patients

    Preclinical & Advanced Discovery

    Preclinical
    Phase 1
    Phase 2
    Pivotal
    Commercial Rights

    Antibody Drug Conjugate (ADC)

    Bispecific Antibody Drug Conjugate

    • Azymetric™
    • ZymeLink™
    Preclinical
    • Solid Tumors
    Full Details

    T Cell Engaging Bispecifics

    T Cell Engaging Bispecifics

    • Azymetric™
    • EFECT™
    Preclinical
    • Solid Tumors
    Full Details

    Microenvironment Modulators

    Microenvironment Modulators

    • Azymetric™
    • EFECT™
    Preclinical
    • Solid Tumors
    Full Details

    Cytokine Receptor Modulators

    Multiple

    • Azymetric™
    • EFECT™
    Preclinical
    • Inflammation
    • Autoimmune
    Full Details
    Explore Candidates

    Three platforms. Endless possibilities.

    Powerful, versatile protein engineering platforms for highly customized therapeutics including cytotoxic anti-tumor biologics, antibody drug conjugates, and immuno-oncology therapies.

    Explore Platforms

    One Zymeworks.

    At Zymeworks, we stand for

    innovation, integrity, collaboration & caring